By harnessing the body’s immune system to detect and destroy tumor cells, immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine.1-4

Although immune checkpoint inhibitors have demonstrated durable clinical responses across several tumor types, these therapies are costly and may present toxic side effects.1,3-6  Comprehensive genomic and proteomic profiling with Caris Molecular Intelligence can help you make more informed therapy decisions when considering immune checkpoint inhibitors.

  1. Topalian SL. N Engl J Med. 2012;366(26):2443-2454. doi:10.1056/NEJMoa1200690.
  2. Patel SP and Kurzrock R. Mol Cancer Ther. 2015;14(4):847-856. doi:10.1158/1535-7163.MCT-14-0983.
  3. Le DT. N Engl J Med. 2015;372:2509-2520. doi:10.1056/NEJMoa1500596.
  4. Rizvi NA. Science. 2015; 384(6230):124-128. doi:10.1126/science.aaa1348.
  5. Rosenberg JE. The Lancet. 2016; 387(10031):1909-1920. doi:10.1016/S0140-6736(16)00561-4.
  6. Motzer RJ. N Engl J Med. 373:1803-1813. doi:10.1056/NEJMoa1510665.
  7. Snyder A. N Engl J Med. 2014; 371:2189-2199. doi:10.1056/NEJMoa1406498.
  8. Mellman I.. Nature. 2011;480:480-489. doi:10.1038/nature10673.
  9. Borghaei H. N Engl J Med. 2015;373:1627-39. doi:10.1056/NEJMoa1507643.
  10. Garon EB. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa1501824.
  11. Taube JM. Clin Cancer Res. 2014;20(19):5064-5074. doi:10.1158/1078-0432.CCR-13-3271.